Millennium announces new chief executive

Millennium Pharmaceuticals has named Deborah Dunsire president and chief executive. Dunsire was previously head of Novartis' North American oncology operations and succeeds Mark Levin, co-founder and chief executive since the Company's inception 12 years ago. Dunsire plans to assume her duties by August 1.
Dunsire said a priority at Millennium would be to strengthen the sales and marketing organization, according to a report in today's New York Times.
Millennium, one of the first companies focusing on genomics, recently shifted gears to developing new drugs rather than searching for genes. The company has two drugs on the market, Integrilin for acute coronary syndrome and Velcade for multiple myeloma. Revenues form sales and alliances were $448 million last year however the company still lost an estimated $252 million.
 

Opinion

How to Shatter the Glass Ceiling

How Pharma Can Benefit from the Transformation of Pharmacy

Newsletters

Live at MM&M Transforming Healthcare

Pharma faces its 'oh, shit' moment

In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.

Merck, Takeda execs: Is AI the new bad app?

One executive referred to AI as a "black box" and as the "Tower of Babel."

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

Admetsys wins the 2017 MM&M Startup Showdown

The artificial pancreas can provide value to the health system.

Top 40 Healthcare Transformers

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts

For the first time MM&M honors a group of 10 agency execs.